Bluebird’s stock falls 21% as it says it will focus on U.S. market for gene therapies, citing ‘European payers’
Shares of Bluebird Bio Inc.
BLUE,
-3.25%
were down 21.6% in premarket trading on Monday after the company announced several setbacks to its business as part of its second-quarter earnings announcement. Bluebird plans to wind down its gene therapy operations…
